Hepatitis E prevalence among HIV infected patients with elevated liver enzymes in the Netherlands  by Hassing, R.J. et al.
SH
l
R
R
a
b
c
d
a
A
R
R
A
K
H
H
S
1
g
a
S
N
a
(
(
(
R
C
T
G
f
R
h
1Journal of Clinical Virology 60 (2014) 408–410
Contents lists available at ScienceDirect
Journal  of  Clinical  Virology
jou rn al hom epage: www.elsev ier .com/ locate / j cv
hort  Communication
epatitis  E  prevalence  among  HIV  infected  patients  with  elevated
iver  enzymes  in  the  Netherlands
.J.  Hassinga,b,∗,  A.A.  van  der  Eijkc,1,  V.  Baptista  Lopesa,2, I.J.  Snijdewinda,2,
.A.  de  Mand,3, S.D.  Pasc,4,  M.E.  van  der  Endea,2
Department of Internal Medicine and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands
Inspectorate of Health Care, The Hague, The Netherlands
Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 6 February 2014
eceived in revised form 12 May  2014
ccepted 17 May  2014
eywords:
IV
epatitis E
a  b  s  t  r  a  c  t
Background:  In recent  years  chronic  hepatitis  E virus  (HEV)  infections  have  been  reported  in  immunosup-
pressed  patients,  including  HIV-positive  patients  with  low  CD4  cell  counts.  Because  of  delayed  anti-HEV
seroconversion  in patients  with  CD4  cell  count  < 200  cells/ml  it is difﬁcult  to draw  ﬁrm  conclusions  on
HEV-seroprevalence  in  a population  of  HIV  positive  patients.
Objectives:  To  determine  the  HEV  seroprevalence  in  a  population  of HIV  infected  patients.
Study  design:  We  retrospectively  analysed  the  HEV  prevalence  in a  population  of 256  HIV infected  patients
with  liver  enzyme  elevations  (LEEs),  using  HEV  speciﬁc  antibody  testing  and HEV-RNA  detection.eroprevalence Results:  Within  this  cohort  we observed  a HEV-seroprevalence  of  11.7%,  without  any  anti-HEV  IgM posi-
tive  or  HEV-RNA  positive  cases.  HEV  seropositivity  was  equally  prevalent  among  different  CD4+ cell  count
groups.
Conclusion:  Although  HIV  infected  patients  in  the  Netherlands  are  at risk  of  acquiring  HEV,  the number
of  acute  infections  is low  and  no chronic  cases  were  found.
©  2014  Elsevier  B.V.  All  rights  reserved.. BackgroundHepatitis E virus (HEV), the only member of the Hepevirus
enus, Hepeviridae family, was ﬁrst described in 1983 [1]. It is
 positive sense single stranded non-enveloped RNA virus. Four
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386-6532/© 2014 Elsevier B.V. All rights reserved.genotypes have been described. Genotypes 1 and 2, are transmitted
by faecal-oral route and responsible for large water-borne HEV out-
breaks in humans in tropical and sub-tropical parts of Asia, Africa
and Central America, with poor hygienic circumstances [2–4]. HEV
genotypes 3 and 4 are found in pigs and other animal species
throughout the world and are thought to be zoonotic in developed
countries. Recently more sensitive assays have become available,
which have detected seroprevalences in non-endemic countries
ranges from 25% to 52%, mostly involving genotype 3 strains [5,6].
In immunocompetent patients HEV is usually a mild to moder-
ate self-limiting disease [7]. In patients with underlying chronic
liver disease a more fulminant course has been reported [8]. Sev-
eral cases of chronic HEV have been reported in recipients of solid
organ transplants (kidney, heart, liver and kidney-pancreas), bone
marrow transplants and in other patients receiving immunosup-
pressive therapy [9,10]. Since 2009 six HEV prevalence studies
conducted in Europe, in total involving 1958 HIV infected patients,
reported 2.6–10.4% positive HEV IgG rates [11–17]. Recent obser-
vations have suggested a delayed anti-HEV seroconversion in HIV
patients with low CD4 cell counts (<200 cells/ml), implying that
serologic observations may  not reﬂect the true seroprevalence
and that cases of chronic hepatitis E virus infections could be
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Table  1
Patient characteristics and HEV serology results in patient subgroups.
Total HEV IgG negative serology HEV IgG positive serology P value
Number of patients (%) 231 204 (88.3%) 27 (11.7%)
Male  (%) 169 (73.2%) 148 (72.9%) 21 (77.8%) 0.59
Median age (SD) 42.2 (±10.2) 41.8 (±10.4) 46.9 (±8.7) 0.29
Origin (%)
The Netherlands 120 (51.9%) 118 (57.8%) 12 (44.4%)
Europe 25 (10.8%) 22 (10.8%) 3 (11.1%) 0.50a
Africa 34 (14.7%) 25 (12.3%) 9 (33.3%) 0.018a
Caribbean/South America 36 (15.6%) 35 (17.2%) 1 (3.7%) 0.15a
Asia 12 (5.2%) 10 (4.9%) 2 (7.4%) 0.37a
Misc 4 (1.7%) 4 (2.0%) 0
ALT  mean (SD) 306.0 (±301.0) 266.0 (±220.2) 440.0 (±466.7) <0.001
AST  mean (SD) 179.0 (±96.1) 182.4 (±96.8) 123.8 (±20.6) 0.13
CD4  cell count/mm3 (SD) 363.0 (±259.0) 348.2 (±250.7) 417.11 (±255.8) 0.95
CD4  cell count (%)
>500 cells/ml 59 (25.6%) 50 (24.8%) 9 (33.3%)
201–500 cells/ml 102 (44.2%) 90 (44.6%) 12 (44.4%) 0.34b
≤200 cells/ml 68 (29.4%) 62 (30.7%) 6 (22.2%) 0.20b
Missing 2 (8.7%) 2 (1.0%) 0
cART use 181 (78.4%) 160 (79.2%) 21 (80.8%) 0.54
Co-morbidities
None  62 (26.8%) 55 (27.0%) 7 (25.9%)
Viral  hepatitis co-infections (HAV, HBV, HCV) 82 (35.5%) 71 (34.8%) 11 (40.7%) 0.45c
Drug-induces hepatitis 28 (12.1%) 26 (12.7%) 2 (7.4%) 0.43c
Hematologic malignancy 12 (5.2%) 11 (5.4%) 1 (3.7%) 0.62c
Opportunistic infections 15 (6.5%) 14 (6.9%) 1 (3.7%) 0.51c
Miscellaneous 32 (13.9%) 27 (13.2%) 5 (18.5%) 0.38c
P value = differences in baseline characteristics between HEV IgG positive and negative patients (p value < 0.05 considered statistically signiﬁcant).
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2a Compared to origin the Netherlands as reference group.
b Compared to CD4 cell count >500 cells/ml as reference group.
c Compared to no co-morbidities as reference group.
issed [13,14]. We  hypothesised that a seroprevalence study in
IV infected patients should also include detection of HEV RNA
ithin the low CD4 cell count group. Alternative explanations for
iver enzyme elevation do not exclude a chronic HEV infection and
ay  be a risk factor for chronic hepatitis E [18].
. Objectives
To determine the HEV seroprevalence by studying HEV speciﬁc
ntibodies, HEV-RNA and CD4 cell count in all HIV infected patients
ith elevated liver enzymes in our hospital.
. Study design
.1. Patients
From all 1879 HIV positive patients in follow-up at the Depart-
ent of Infectious Diseases of the Erasmus Medical Center between
une 2006 and June 2011, we selected patients with at least one
pisode of elevated alanine aminotransferase (ALT) or aspartate
minotransferase (AST) levels thrice the upper limit of normal (ALT
LN 30 IU/l). Stored EDTA-plasma samples (−80 ◦C) were used for
he detection of HEV speciﬁc antibodies and HEV-RNA. Because
ost of the outpatients are screened for HIV viral load and liver
nzymes at the same time during combined antiretroviral ther-
py (cART), EDTA-plasma samples were available from the same
ime as liver enzyme determination in most of the cases. We
etrieved information from the medical records on ethnicity, co-
orbidities including factors which could result in LEEs such as
iral and drug-induced hepatitis, and also opportunistic infections,
D4 cell counts and usage of cART at the time of the LEEs. We
btained approval for our study by the Medical Ethical Review
oard of the Erasmus Medical Center (reference number MEC-
011-438).3.2. HEV speciﬁc antibody detection
For both HEV speciﬁc IgM and HEV speciﬁc IgG detection
in serum or EDTA-plasma samples the commercially available
enzyme-linked immunosorbent assay (ELISA) (Wantai, Beijing,
China) was  used according to the manufacturer’s instructions.
3.3. HEV-RNA detection
All samples were screened for the presence of HEV RNA by an
internally controlled quantitative real-time RT-PCR, described pre-
viously [19]. The RT-PCR has a lower limit of detection (95% hit rate)
of 143 IU/ml as determined by the 1st WHO  standard for HEV RNA
NAT-Based assays (6329/10, Paul Ehrlich Institute, Germany).
3.4. Statistical analysis
Baseline characteristics were compared between HEV IgG
positive and negative patients. For continuous parameters with
a normal distribution, T test was used. For categorical or
dichotomized parameters, proportions between groups were com-
pared using the Chi squared test or the Fisher’s exact test. A P value
<0.05 was considered statistically signiﬁcant.
4. Results
We identiﬁed 256 patients with LEEs of more than three times
the upper limit of normal. Stored samples of 231 patients were
available for testing. Patient characteristics are shown in Table 1.
In 26.8% of the patients there was  no explanation for the elevated
transaminases. Of the 231 stored samples, 11.7% tested positive for
anti-HEV IgG, none of the samples was anti-HEV IgM positive.ALT was  signiﬁcantly higher in HEV IgG positive patients
compared to HEV IgG negative patients (Table 1). HEV seropos-
itivity was equally prevalent among the three different CD4 cell
count groups (Table 1). In 75 patients with low CD4 cell counts
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≤200 cells/ml), six patients showed positive anti-HEV IgG sero-
ogy. HEV-RNA was not detected in any of the 231 samples.
A statistically signiﬁcant difference between the proportions of
ositive HEV IgG seroprevalence was observed between patients
riginating from Africa compared to the Netherlands. In HIV
nfected patients originating from the Netherlands the HEV sero-
revalence was 9% (12 of 120 patients). In the other ethnic groups,
atients from the Caribbean and/or South America had a low HEV
eroprevalence of 2.8% (1 of 36 patients), while patients from Sub-
aharan Africa had a HEV seroprevalence of 26.5% (9 of 34 patients).
. Discussion
We  retrospectively analysed the HEV seroprevalence and HEV
iraemia in a population of 256 HIV infected patients with LEEs,
sing HEV speciﬁc antibody and HEV-RNA detection. We  observed
 HEV seroprevalence of 11.7%, without any anti-HEV IgM positive
r HEV-RNA positive cases. The results of HEV seropositivity are
ower compared to observations in a Dutch study of blood donors
hich showed 26.7% reactivity for anti-HEV IgG using the same
LISA [6]. This may  be explained by the younger age of our patients
median 42 yrs) compared to the donors (>50 yrs).
Our results are in agreement with several other reports in HIV
nfected groups from industrialised countries concerning the rate
f HEV seropositivity which also showed only six patients with
etectable HEV-RNA (0.2%) indicative of chronic HEV infection in
550 HEV IgG positive HIV infected patients [11–16,20–22]. None
f the HEV IgG reactive patients from a HIV infected cohort in the
SA developed chronic HEV. The rare occurrence of chronic hepati-
is E may  be explained by a high coverage of cART in HIV infected
atients, preventing a strongly decreased immune response. How-
ver, in HIV infected patients in Africa, with a substantial rate
f positive anti-HEV IgG in adult HIV infected Ghanese (45.3%)
nd Camerounese (14.2%) patients, with a signiﬁcant proportion
f cART-naïve and severely immunocompromised patients in the
tudy population, no chronic HEV was observed [23]. The absence
f chronic HEV in this African study may  be due to the prevailing
enotypes 1 and 2 in this region, which may  not have the potential
o cause chronic HEV like genotype 3. Seroprevalence of anti-HEV
gG differed between ethnicities, but did not differ between differ-
nt CD4 cell counts. These seroprevalence data on HEV conﬁrm that
EV should be included in the differential diagnose of patients with
igns of (acute) hepatitis.
A limitation of our study is that we selected patients with ele-
ated ALT or AST levels thrice the upper limit of normal and could
herefore easily have missed patients with HEV with mild to mod-
rate liver function abnormalities.
In conclusion, although HEV seroprevalence in Dutch, cART
reated, HIV-infected patients with LEE is 11.7%, no chronic HEV
as found in our cohort. Based on our observation, general
creening for anti-HEV serology and HEV viraemia in this patient
roup may  not be necessary.
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